An interventional study of Re-Ascent from sea level to 2850m in High Altitude, Healthy and Healthy Adult, sponsored by Silvia Ulrich Somaini. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Silvia Ulrich Somaini · Not applicable, Interventional, and Supportive care
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.
The aim of this research is to investigate the pulmonary resistance (sPAP/CO) by echocardiography and other hemodynamic outcomes before and after re-ascent (sea level for 7 days vs. re-ascent to 2850m) in healthy individuals, who permanently live at high altitude over 2600m
216 studies on the registry are indexed under Altitude Sickness; 46 are open to participants now.
This study's planned enrollment of 14 is below the median of 34 across 178 interventional studies indexed under Altitude Sickness.
Browse Altitude Sickness studies →Silvia Ulrich Somaini is the lead sponsor of 17 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assessment of pulmonary resistance (sPAP/CO) and other hemodynamic outcomes after 7 days at sea level and after re-ascent at 2850m
Behavioral: Re-Ascent from sea level to 2850m
After 7 days at sea level return/re-ascent to their usual living altitude at 2850m
Pulmonary resistance (sPAP/CO) after re-ascent to 2850m
Difference in sPAP/CO by echocardiography between sea level (after one-week stay) and day after re-ascent at 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to the day after re-ascent
Tricuspid regurgitation velocity TRV after re-ascent to 2850m
Difference/change in tricuspid regurgitation velocity TRV between sea level (after one-week stay) and day after re-ascent at 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to the day after re-ascent
Cardiac output CO after re-ascent to 2850m
Difference/change in cardiac output CO between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to the day after re-ascent
Tricuspid annular plan systolic excursion TAPSE after re-ascent to 2850m
Difference/change in tricuspid annular plan systolic excursion TAPSE between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to day after re-ascent
Right ventricular strain after re-ascent to 2850m
Difference/change in right ventricular strain between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to day after re-ascent
Right atrial pressure RAP after re-ascent to 2850m
Difference/change in rightatrial pressure RAP between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to day after re-ascent
Fractional area change FAC after re-ascent to 2850m
Difference/change in fractional area change FAC between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
Time frame: From Day 5-7 at sea level to day after re-ascent
PaO2 after re-ascent to 2850m
Difference/change in PaO2 (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
Time frame: From Day 7 at sea level to day after re-ascent (time frame of 3 days)
PaCO2 after re-ascent to 2850m
Difference/change in PaCO2 (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
Time frame: From Day 7 at sea level to day after re-ascent (time frame of 3 days)
Hemoglobin after re-ascent to 2850m
Difference/change in hemoglobin (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
Time frame: From Day 7 at sea level to day after re-ascent (time frame of 3 days)
pH after re-ascent to 2850m
Difference/change in pH (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
Time frame: From Day 7 at sea level to day after re-ascent (time frame of 3 days)
Pulmonary resistance (sPAP/CO) pre-descent to after re-ascent
Difference/change in pulmonary resistance (sPAP/CO) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Tricuspid regurgitation velocity TRV pre-descent to after re-ascent
Difference/change in tricuspid regurgitation velocity TRV at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Cardiac output CO pre-descent to after re-ascent
Difference/change in cardiac output CO at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Tricuspid annular plan systolic excursion TAPSE pre-descent to after re-ascent
Difference/change in tricuspid annular plan systolic excursion TAPSE at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Right ventricular strain pre-descent to after re-ascent
Difference/change in right ventricular strain at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Right atrial pressure RAP pre-descent to after re-ascent
Difference/change in right atrial pressure at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Fractional area change FAC pre-descent to after re-ascent
Difference/change in fractional area change FAC at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
PaO2 pre-descent to after re-ascent
Difference/change in PaO2 (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
PaCO2 pre-descent to after re-ascent
Difference/change in PaCO2 (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Hemoglobin pre-descent to after re-ascent
Difference/change in hemoglobin (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
pH pre-descent to after re-ascent
Difference/change in pH (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
Time frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
Plan to share: Yes — Data will be provided upon request and based on a clear intention reviewed by an ethical review board.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Silvia Ulrich Somaini